Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phthalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA4 | P22748 | 3/20 | 0.58 |
| ▸ | CA7 | P43166 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalic Acid SCHEMBL30100313 | 0.97 | ALDH1A1 (0.82) | ALDH1A1ALOX15AKR1C3CA12CA1 | |
| Phthalic Acid SCHEMBL29358471 | 0.97 | ALDH1A1 (0.82) | ALDH1A1ALOX15AKR1C3CA12CA1 | |
| Phthalic Acid SCHEMBL2777 | 0.97 | ALDH1A1 (0.82) | ALDH1A1ALOX15AKR1C3CA12CA1 | |
| Phthalic Acid SCHEMBL11323294 | 0.97 | ALDH1A1 (0.82) | ALDH1A1ALOX15AKR1C3CA12CA1 | |
| Phthalic Acid SCHEMBL27618507 | 0.97 | ALDH1A1 (0.82) | ALDH1A1ALOX15AKR1C3CA12CA1 | |
| Phthalic Acid SCHEMBL2561870 | 0.97 | ALDH1A1 (0.82) | ALDH1A1ALOX15AKR1C3CA12CA1 | |
| Phthalic Acid SCHEMBL7897915 | 0.97 | ALDH1A1 (0.82) | ALDH1A1ALOX15AKR1C3CA12CA1 | |
| Phthalic Acid SCHEMBL8398555 | 0.97 | ALDH1A1 (0.82) | ALDH1A1ALOX15AKR1C3CA12CA1 | |
| Phthalic Acid SCHEMBL8750273 | 0.94 | ALDH1A1 (0.78) | ALDH1A1ALOX15AKR1C3CA12CA1 | |
| Phthalic Acid SCHEMBL6383293 | 0.94 | ALDH1A1 (0.78) | ALDH1A1ALOX15AKR1C3CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628311-B1 | A PROCESS FOR THE PREPARATION OF A MODIFIED RELEASE MULTIPLE UNIT ORAL DOSAGE FORM OF DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE | INIBSA GINECOLOGIA S A (ES) | 2020-11-11 | — | — | EP | claimed |
| EP-3628311-A1 | A PROCESS FOR THE PREPARATION OF A MODIFIED RELEASE MULTIPLE UNIT ORAL DOSAGE FORM OF DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE | Inibsa Ginecologia, S.A. (ES) | 2020-04-01 | — | — | EP | claimed |
| CN-1859909-B | Solid dispersions comprising tacrolimus | LIFECYCLE PHARMA AS | 2011-04-06 | — | — | CN | claimed |
| CN-101869561-A | The improvement release composition that contains tacrolimus | LIFECYCLE PHARMA AS | 2010-10-27 | — | — | CN | claimed |
| CN-1859909-A | Solid dispersions comprising tacrolimus | LIFECYCLE PHARMA AS (DK) | 2006-11-08 | — | — | CN | claimed |
| CN-1859910-A | Modified release composition containing tacrolimus | LIFECYCLE PHARMA AS (DK) | 2006-11-08 | — | — | CN | claimed |
| CN-114727950-A | 1- (((2S,3S,4S) -3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl) methoxy) -7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms | 辉瑞大药厂 | 2022-07-08 | — | — | CN | disclosed |
| CN-105101952-B | Oral sustained release formulation of tofacitinib | 辉瑞公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-107567440-B | Pyroglutamic acid vortioxetine | H.隆德贝克有限公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-112741816-A | Novel colon drug delivery system | 江苏集萃新型药物制剂技术研究所有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-112739222-A | Anti-aging agent and anti-aging method | 田中惠 | 2021-04-30 | — | — | CN | disclosed |
| CN-111939154-A | Anti-aging composition, application thereof, and health food and medicine containing anti-aging composition | 周琛 | 2020-11-17 | — | — | CN | disclosed |
| EP-3628311-B1 | A PROCESS FOR THE PREPARATION OF A MODIFIED RELEASE MULTIPLE UNIT ORAL DOSAGE FORM OF DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE | INIBSA GINECOLOGIA S A (ES) | 2020-11-11 | — | — | EP | disclosed |
| CN-1859909-A | Solid dispersions comprising tacrolimus | LIFECYCLE PHARMA AS (DK) | 2006-11-08 | — | — | CN | disclosed |
| CN-1859910-A | Modified release composition containing tacrolimus | LIFECYCLE PHARMA AS (DK) | 2006-11-08 | — | — | CN | disclosed |
| CN-1823749-A | Sertraline salts and sustained release dosage forms of sertraline | PFIZER (US) | 2006-08-30 | — | — | CN | disclosed |
| CN-1256085-C | Sertraline salts and sustained release dosage forms of sertraline | PFIZER (US) | 2006-05-17 | — | — | CN | disclosed |
| CN-1628648-A | Loxoprofen sodium sustained release preparation | UNIV FUDAN (CN) | 2005-06-22 | — | — | CN | disclosed |
| CN-1489476-A | Method for preparing biological material and preparation prepared thereby | ب���ƻ�����˾ | 2004-04-14 | — | — | CN | disclosed |
| CN-1261793-A | Sertraline salts and sustained release dosage forms of sertraline | PFIZER (US) | 2000-08-02 | — | — | CN | disclosed |